Endologix LLC announced the 24-month results of the DETOUR2 Study. Percutaneous Transmural Arterial Bypass (PTAB) with the DETOUR™? System, recently received PMA Approval from the FDA on June 7, 2023.

This system offers a unique approach to treating complex peripheral arterial disease (PAD), enabling physicians to percutaneously bypass lesions in the superficial femoral artery, by using stents routed through the femoral vein to restore blood flow to the leg. The DETOUR System is comprised of the ENDOCROSSTM device and TORUSTM stent grafts. The results: presented included: Ninety-six% (96%) of enrolled patients had chronic total occlusions, with a mean lesion length of 32.7cm.

Technical success was achieved in 100% of treated patients and the primary safety endpoint was surpassed with a 30-day MAE rate of 7.0% The freedom from CD-TLR at 24 months was 76.7%, and secondary patency was 82.3%. The freedom from symptomatic DVT was 96.5% at 24 months. The freedom from major lower limb amputation was 98.5%.

The freedom from major lower limb limb amputation was 98. 5% at 24 months.